Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease

Document first published:: 24 September 2020
Page updated:: 17 September 2021
Topic:: Commissioning, Medicine, Specialised commissioning
Publication type:: Policy or strategy, Report

NHS England will commission vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease in accordance with the criteria outlined in these documents.

Document

Clinical commissioning policy: Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease

Clinical commissioning policy: Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease

PDF
112 KB
20 pages

Document

Clinical panel report: Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease

Clinical panel report: Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease

PDF
27 KB
2 pages

Document

Consultation report: Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease

Consultation report: Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease

PDF
54 KB
4 pages

Document

CPAG summary report: Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease

CPAG summary report: Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease

PDF
65 KB
7 pages

Document

Evidence review: Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease

Evidence review: Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease

PDF
323 KB
45 pages

Document

Stakeholder engagement: Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease

Stakeholder engagement: Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease

PDF
28 KB
2 pages

Document

Equality and Health Inequalities Impact Assessment (EHIA): Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease

Equality and Health Inequalities Impact Assessment (EHIA): Vonicog alfa for the treatment and prevention of bleeding in adults with von Willebrand disease

PDF
82 KB
11 pages